Previous 10 | Next 10 |
— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine’s artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In April 2023, the U.S....
-- Presentations to be webcast on www.exelixis.com -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in September: 2023 Wells Fargo Healthcare C...
2023-08-30 08:00:00 ET Investing in stocks isn't just for the rich and famous since quality stocks can be found at almost any price. Some are trading for well above $1,000 per share, while others go for less than $100 apiece. However, finding stocks under $100 may be better for those who ar...
2023-08-30 07:00:00 ET Summary Exelixis issued two important releases regarding its lead molecule cabozantinib, showing positive results in prostate cancer and advanced pancreatic and extra-pancreatic neuroendocrine tumors. The company's finances and liquidity are solid, with posi...
Shares of Exelixis, Inc. (NASDAQ: EXEL) traded at a new 52-week high today and are currently trading at $22.27. So far today, approximately 432.99k shares have been exchanged, as compared to an average 30-day volume of 2.79M shares. Exelixis, Inc., an oncology-focused biotechnology company, f...
2023-08-24 08:47:07 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis lead product hits main goal in Phase 3 prostate cancer trial Exelixis a new over...
2023-08-24 08:40:38 ET Bruush Oral Care ( BRSH ) +62% . Hitek Global ( HKIT ) +19% . Guess? GES +16% on Q2 earnings release . Groupon ( GRPN ) +14% . Splunk SPLK +14% on Q2 earnings release . Eos Energy Enterprises ( EOSE ) ...
– CABINET trial will be unblinded and stopped early due to a dramatic improvement in efficacy per a unanimous recommendation by The Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board – – Based on positive results, findings will b...
2023-08-24 07:30:00 ET Following the market's gloomy 2022, this year has been a breath of fresh air with the S&P 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. C ystic fibrosis specialist Vertex Pharmaceuticals (NASD...
2023-08-24 03:43:27 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis lead product hits main goal in Phase 3 prostate cancer trial For further details...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...